Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLC

Vassiliki Papadimitrakopoulou, MD
Published: Wednesday, Oct 10, 2018



Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer (NSCLC).

For thoracic oncologists to do better with immunotherapy, they need to better select patients for clinical trials, Papadimitrakopoulou says. More emphasis is also needed on biomarker work in clinical trials because there is concrete evidence that this ultimately leads to improved outcomes. In the KEYNOTE-024 and CheckMate-227 studies, PD-L1 expression and tumor mutation burden, respectively, emerged as biomarkers for immune response. Additional biomarkers predictive of response to single agents and combination therapies would be useful.

Another strategy to consider are neoadjuvant clinical trials that are able to provide enough materials at surgical resection for researchers to identify the mechanism of the drug. Umbrella clinical trials—where patients are allocated into groups based on the therapy they are most likely to derive benefit from—are also a good strategy, Papadimitrakopoulou says.
SELECTED
LANGUAGE


Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer (NSCLC).

For thoracic oncologists to do better with immunotherapy, they need to better select patients for clinical trials, Papadimitrakopoulou says. More emphasis is also needed on biomarker work in clinical trials because there is concrete evidence that this ultimately leads to improved outcomes. In the KEYNOTE-024 and CheckMate-227 studies, PD-L1 expression and tumor mutation burden, respectively, emerged as biomarkers for immune response. Additional biomarkers predictive of response to single agents and combination therapies would be useful.

Another strategy to consider are neoadjuvant clinical trials that are able to provide enough materials at surgical resection for researchers to identify the mechanism of the drug. Umbrella clinical trials—where patients are allocated into groups based on the therapy they are most likely to derive benefit from—are also a good strategy, Papadimitrakopoulou says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x